Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). It acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA), resulting in a reduction of abnormal electrical activity in the brain.
## Primary Indications
* Adjunctive treatment for seizures in patients with Lennox-Gastaut Syndrome (LGS).
## Adult Dosing
* **Initial:** 5 mg twice daily.
* **Maintenance:** Titrate up to a maximum of 20 mg twice daily (total 40 mg/day) based on response and tolerability. Doses should be adjusted slowly.
## Pediatric Dosing
* **Ages 2 to <10 years:**
* Initial: 2.5 mg once daily.
* Maintenance: Titrate up to a maximum of 10 mg twice daily (total 20 mg/day).
* **Ages 10 years and older:**
* Initial: 5 mg twice daily.
* Maintenance: Titrate up to a maximum of 20 mg twice daily (total 40 mg/day).
* **Note:** Dosing for children younger than 2 years is not established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are universally established, but reduced doses and slower titration may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustments are universally established.
* **Concomitant Medications:** Dose reduction may be necessary for patients taking other CNS depressants or CYP2C19 inhibitors.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Acute narrow-angle glaucoma.
## Adverse Effects
* **Common:** Somnolence, constipation, decreased appetite, fatigue, aggression, irritability, difficulty with coordination.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Additive sedative effects, increased risk of respiratory depression.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** Can increase clobazam plasma concentrations, potentially leading to increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** Can decrease clobazam plasma concentrations.
* **Other Anticonvulsants:** Potential for altered efficacy or increased CNS side effects.
## Monitoring
* Monitor for therapeutic efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of suicidal ideation.
* Monitor for signs of tolerance and dependence, especially upon discontinuation.
* Consider therapeutic drug monitoring if efficacy is suboptimal or toxicity is suspected, although therapeutic ranges are not well-defined.
## Clinical Pearls
* Clobazam is often used as an add-on therapy for LGS seizures.
* Due to its long half-life, clobazam can accumulate, especially in patients with hepatic impairment.
* Sudden discontinuation can lead to withdrawal symptoms; gradual tapering is recommended.
* Behavioral and psychiatric side effects, including aggression and suicidal behavior, have been reported and require close monitoring.
* The risk of severe cutaneous reactions, though rare, necessitates patient and provider education to recognize early signs.
***
**Disclaimer:** This information is intended for clinical use and does not substitute for professional medical judgment. Always verify current prescribing information with the official product labeling and consult relevant guidelines before making any treatment decisions.
